BioStock: Evaxion and ExpreS²ion to collaborate on CMV vaccine

Evaxion Biotech has signed a Vaccine Discovery Collaboration Agreement with ExpreS²ion Biotech for the joint development of a novel cytomegalovirus vaccine candidate. With their AI platform RAVEN, Evaxion will identify the antigen targets and design the new vaccine based on those, and ExpreS²ion will manufacture the antigen constructs necessary for vaccine development. BioStock spoke to the CEOs of both companies – Per Norlén for Evaxion and Bent U Frandsen for ExpreS²ion – to learn more about the agreement.

Read the interview with Per Norlén and Bent U Frandsen at biostock.se:

Evaxion and ExpreS²ion to collaborate on CMV vaccine - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/